

SmartPA Criteria Proposal

Drug/Drug Class:	Calcium Channel Blockers, Non-Dihydropyridine PDL Edit
First Implementation Date:	September 1, 2004
Proposed Date:	September 15, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	☒ Existing Criteria ☐ Revision of Existing Criteria ☐ New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Calcium channel blocking agents slow the movement of calcium across the cell membrane resulting in the reduction of contraction of both smooth and cardiac muscle and cells within the heart and blood vessels. These agents are generally classified into two groups, according to their chemical structure: dihydropyridines (amlodipine, felodipine, isradipine, nicardipine, nifedipine, and nisoldipine), and non-dihydropyridines (diltiazem and verapamil). Dihydropyridines (DHPs) have greater selectivity for vascular smooth muscle with little direct effect on the myocardium; non-dihydropyridines (non-DHPs) have less selective vasodilator activity and have a direct effect on the myocardium.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	• Cartia XT® • Dilt XR • Diltiazem CD • Diltiazem ER Caps • Diltiazem HCl • Diltiazem XR • Taztia XT® • Verapamil HCl • Verapamil ER Caps/Tabs • Verapamil SR	• Calan® • Calan SR® • Cardizem • Cardizem CD® • Cardizem LA® • Diltiazem LA Tabs • Matzim LA® • Tiadylt® ER • Tiazac® • Verapamil ER PM • Verelan® • Verelan PM®

Type of Criteria: ☐ Increased risk of ADE
☐ Appropriate Indications

☒ Preferred Drug List
☐ Clinical Edit

Data Sources: ☒ Only Administrative Databases

☐ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Calcium Channel Blockers, Non-Dihydropyridine
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents:
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine Analysis: "Calcium Channel Blockers", UMKC-DIC; July 2022.
- Evidence-Based Medicine and Fiscal Analysis: "Calcium Channel Blocker Agents (Non-dihydropyridines) – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2021.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.